Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results

Dow Jones

05/04

By Adriano Marchese

Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment.

Shares rose 14.6% in ahead of the morning bell to $144.

The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA.

The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint.

Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug.

After that, the company will also share the data with regulators in other countries, it said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

May 04, 2026 07:30 ET (11:30 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2632930986"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2632930986\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2632930986?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2632930986","market":"other","top_or_hot":-1,"title":"Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment. \n</p>\n<p>\n  Shares rose 14.6% in ahead of the morning bell to $144. \n</p>\n<p>\n  The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA. \n</p>\n<p>\n  The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint. \n</p>\n<p>\n  Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug. \n</p>\n<p>\n  After that, the company will also share the data with regulators in other countries, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 04, 2026 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Celcuity Shares Climb on Positive Breast-Cancer Drug Trial Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCelcuity Shares Climb on Positive Breast-Cancer Drug Trial Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-04 19:30</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment. \n</p>\n<p>\n  Shares rose 14.6% in ahead of the morning bell to $144. \n</p>\n<p>\n  The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA. \n</p>\n<p>\n  The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint. \n</p>\n<p>\n  Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug. \n</p>\n<p>\n  After that, the company will also share the data with regulators in other countries, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 04, 2026 07:30 ET (11:30 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2632930986","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2632930986","pubTimestamp":1777894200,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment.Shares rose 14.6% in ahead of the morning bell to $144.The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA.The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint.Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug.After that, the company will also share the data with regulators in other countries, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CELC":"Celcuity Inc"},"translate_title":"Celcuity股价因乳腺癌药物试验结果积极而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CELC":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for its proposed breast-cancer treatment. \n\n\n  Shares rose 14.6% in ahead of the morning bell to $144. \n\n\n  The clinical-stage biotechnology company said late Friday that it received positive top-line results from its Viktoria-1 clinical trial for gedatolisib, used with standard hormone-blocking treatments, in people with a common type of advanced breast-cancer mutation called PIK3CA. \n\n\n  The drug showed a statistically significant and clinically meaningful improvement in progression-free survival, as well as for its secondary endpoint. \n\n\n  Celcuity said it plans to send the study results to the Food and Drug Administration for an expanded approval of the drug. \n\n\n  After that, the company will also share the data with regulators in other countries, it said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 07:30 ET (11:30 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}